 BridgeBio Pharma Inc NASDAQ: BBIO and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i LGMD2i. LGMD2i is an inherited recessive muscular dystrophy caused by mutation of fukutin-related protein FKRP, leading to chronic muscle injury and loss, muscle weakness, and disability. 